Stock Taper
OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS
NXTC
NEXTCURE, INC.
NASDAQ
$7.18
▲ UP 5.90% (0.40)

KEY STATISTICS

Market Cap$25.03 M
52w High$15.74
52w Low$1.55
Dividend Yield—
Frequency—
P/E-0.83
Volume85.63K
Shares Out.3.61M

COMPANY

LEADERSHIP

Michael S. Richman
CHIEF EXECUTIVE
Michael S. Richman

COMPENSATION 2026

Salary$609,258
Stock Awards$0
Incentive Plan Pay$122,000
All Other Comp.$21,264
Total$941,692

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 9, 2019
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
40

PRICE TARGET

Target High$20.00
Target Low$20.00
Target Median$20.00
Target Consensus$20.00

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.—
NOV
4
WED

SPLIT RECORD

DATETYPERATIO
2025-07-14Reverse1:12

ETFS HOLDING THIS STOCK

ETFS HOLDING
15
LISTED HERE
4
RANKED BY POSITION SIZE
VTS.AX
0.00%
123.3K
IWC
0.00%
9.3K
PQ
PQSG
0.16%
2.9K
DFMC
0.00%
2.7K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
80.65%
HOLDERS
32
TOP 8 OF 32 · RANKED BY POSITION SIZE
Hillhouse Investment Management, Ltd.
978.6K sh
$14.66M
Blackrock Inc.
761.2K sh
$1.21M
Affinity Asset Advisors, LLC
241.8K sh
$2.58M
Ikarian Capital, LLC
238.3K sh
$2.51M
Sofinnova Investments, Inc.
222.7K sh
$2.38M
Silverarc Capital Management, LLC
176.1K sh
$1.88M
Pfizer Inc
153.4K sh
$1.54M
Opaleye Management Inc.
141.2K sh
$1.51M

PRICE

$7.18 ▲ UP 5.90% (+$0.40)
OVERLAYS
$6.25$6.50$6.75$7.009:34 AM10:38 AM11:42 AM12:47 PM1:51 PM2:55 PM3:59 PM7.18

About NextCure, Inc.

https://www.nextcure.com ↗

NextCure, Inc. is a clinical-stage biopharmaceutical company developing novel immunomedicines like NC318 and NC410 to treat cancer and immune diseases, with multiple candidates in clinical and preclinical trials.

INDUSTRY

Biotechnology

A PRODUCT NEXTCURE, INC. IS KNOWN FOR

SIM0505
SIM0505

SIM0505 is a Phase 1 clinical-stage antibody-drug conjugate by NextCure targeting advanced solid tumors, especially platinum-resistant ovarian cancer, and is a key part of their pipeline for developing targeted cancer therapies.

COMPETITORS

COMPETITOR
ADCT COMPARE
CGEN COMPARE
MGNX COMPARE
STRO COMPARE

NextCure in 2025

SENTIMENT: + POSITIVE
Neil Shahrestani
FINANCIAL · NOVEMBER 2025

NextCure Secures $21.5 Million in Private Placement to Fund Operations into 2027

NextCure, Inc. announced and closed a $21.5 million private placement of common stock with a group of institutional and healthcare-focused investors. This financing is intended to extend the company's cash runway into the first half of 2027, allowing it to reach key proof-of-concept data readouts in 2026 for its two lead antibody-drug conjugate (ADC) programs.

PARTNERSHIP · Q2 2025 · IN PROGRESS

NextCure In-Licenses Promising Antibody-Drug Conjugate SIM0505 in Strategic Partnership with Simcere Zaiming

NextCure entered into a significant strategic partnership with Simcere Zaiming, acquiring the global development and commercialization rights for SIM0505, a clinical-stage antibody-drug conjugate (ADC), outside of Greater China. This move strategically expands NextCure's oncology pipeline, positioning them with two key ADC candidates, SIM0505 and their existing LNCB74.

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book4
Overall Score2

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
Ladenburg Thalmann BUY

SECTORS PEERS

PEERPRICE
QTTB$8.00COMPARE
ANTX$4.53COMPARE
VRCA$4.23COMPARE
BOLD$2.56COMPARE
TAOX$3.65COMPARE
JSPR$0.56COMPARE
PLUR$1.00COMPARE
INTS$3.70COMPARE

INSIDER TRADES

★
OTHER: FORMER 10% OWNER
Simcere Zaiming, Inc.
Sale · 30.0K shares
2026-08-10
★
10 PERCENT OWNER
ADAR1 Capital Management, LLC
Purchase · 3.3K shares
2026-07-31
★
10 PERCENT OWNER
ADAR1 Capital Management, LLC
Purchase · 25.0K shares
2026-07-31
★
10 PERCENT OWNER
ADAR1 Capital Management, LLC
Purchase · 8.0K shares
2026-07-31